ID: ALA5091599

Max Phase: Preclinical

Molecular Formula: C47H60FN7O6S

Molecular Weight: 870.11

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](NC(=O)CCCCCCCCCCC(=O)Nc2ccc(C(=O)Nc3ccc(F)cc3N)cc2)C(C)(C)C)cc1

Standard InChI:  InChI=1S/C47H60FN7O6S/c1-30-42(62-29-51-30)32-17-15-31(16-18-32)27-50-45(60)39-26-36(56)28-55(39)46(61)43(47(2,3)4)54-41(58)14-12-10-8-6-5-7-9-11-13-40(57)52-35-22-19-33(20-23-35)44(59)53-38-24-21-34(48)25-37(38)49/h15-25,29,36,39,43,56H,5-14,26-28,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t36-,39+,43+/m1/s1

Standard InChI Key:  NEDMKPKINQQVSY-JLSVEMTHSA-N

Associated Targets(Human)

VHL/Histone deacetylase 3 77 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 1 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 2 81 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 870.11Molecular Weight (Monoisotopic): 869.4310AlogP: 7.74#Rotatable Bonds: 20
Polar Surface Area: 195.85Molecular Species: NEUTRALHBA: 9HBD: 6
#RO5 Violations: 3HBA (Lipinski): 13HBD (Lipinski): 7#RO5 Violations (Lipinski): 4
CX Acidic pKa: 12.67CX Basic pKa: 2.78CX LogP: 5.89CX LogD: 5.89
Aromatic Rings: 4Heavy Atoms: 62QED Weighted: 0.04Np Likeness Score: -0.82

References

1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT..  (2022)  Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.,  65  (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179]

Source